TYRA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tyra Biosciences Inc (TYRA) is not a strong buy at this moment for a beginner investor with a long-term focus. While the company has promising prospects in its pipeline and favorable analyst ratings, the lack of recent financial performance data, insider selling trends, and no significant trading signals suggest holding off on immediate investment. The stock may be worth revisiting closer to key clinical readouts in 2026.
The MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 51.588, showing no clear overbought or oversold conditions. Moving averages are converging, suggesting indecision in the market. Key resistance levels are at 29.373 and 30.654, while support levels are at 27.299 and 25.224.
Analysts have initiated coverage with strong Buy ratings and price targets ranging from $50 to $56, indicating confidence in the company's lead asset dabogratinib.
The company is well-funded with $383.5M in cash, supporting operations into the second half of
Promising pipeline with potential approvals across multiple indications in oncology and rare diseases.
Insiders are selling, with a significant increase of 100.98% in the last month.
No recent news or updates to drive immediate price action.
Lack of financial data and valuation metrics to assess the company's current financial health.
No financial data available for analysis.
Analysts are generally bullish, with multiple Buy ratings and price targets in the $50-$56 range. However, Wolfe Research has a Peer Perform rating, citing limited near-term upside until safety de-risking is confirmed.
